AU2019316036A1 - Bioavailable oral dosage forms - Google Patents

Bioavailable oral dosage forms Download PDF

Info

Publication number
AU2019316036A1
AU2019316036A1 AU2019316036A AU2019316036A AU2019316036A1 AU 2019316036 A1 AU2019316036 A1 AU 2019316036A1 AU 2019316036 A AU2019316036 A AU 2019316036A AU 2019316036 A AU2019316036 A AU 2019316036A AU 2019316036 A1 AU2019316036 A1 AU 2019316036A1
Authority
AU
Australia
Prior art keywords
compound
sdi
subject
pharmaceutical composition
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019316036A
Other languages
English (en)
Inventor
Mandar V. Dali
Akm Nasir Uddin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67766269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2019316036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of AU2019316036A1 publication Critical patent/AU2019316036A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019316036A 2018-08-03 2019-08-02 Bioavailable oral dosage forms Abandoned AU2019316036A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714182P 2018-08-03 2018-08-03
US62/714,182 2018-08-03
PCT/US2019/044853 WO2020028778A1 (en) 2018-08-03 2019-08-02 Bioavailable oral dosage forms

Publications (1)

Publication Number Publication Date
AU2019316036A1 true AU2019316036A1 (en) 2021-03-04

Family

ID=67766269

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019316036A Abandoned AU2019316036A1 (en) 2018-08-03 2019-08-02 Bioavailable oral dosage forms

Country Status (23)

Country Link
US (1) US20210205225A1 (https=)
EP (1) EP3829544A1 (https=)
JP (1) JP2021532193A (https=)
KR (1) KR20210041589A (https=)
CN (1) CN112752570A (https=)
AR (1) AR115913A1 (https=)
AU (1) AU2019316036A1 (https=)
BR (1) BR112021001859A2 (https=)
CA (1) CA3107737A1 (https=)
CL (1) CL2021000271A1 (https=)
CO (1) CO2021001979A2 (https=)
CR (1) CR20210093A (https=)
EA (1) EA202190429A1 (https=)
EC (1) ECSP21011795A (https=)
IL (1) IL280471A (https=)
MX (1) MX2021001364A (https=)
NI (1) NI202100006A (https=)
PE (1) PE20211410A1 (https=)
PH (1) PH12021550237A1 (https=)
SG (1) SG11202100984VA (https=)
TN (1) TN2021000021A1 (https=)
TW (1) TW202019414A (https=)
WO (1) WO2020028778A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
CN112028888B (zh) * 2020-09-11 2021-08-20 中国药科大学 一种化合物及其制备方法和用途
US20250186437A1 (en) 2021-12-31 2025-06-12 Ptc Therapeutics, Inc. Carboline compounds and use thereof
US20220151938A1 (en) * 2022-01-28 2022-05-19 Ptc Therapeutics, Inc. Tablet for use in treating huntington's disease and method of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249799A1 (en) 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
UA92317C2 (ru) 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
US20120202801A1 (en) * 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
WO2017091373A1 (en) * 2015-11-25 2017-06-01 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms

Also Published As

Publication number Publication date
EP3829544A1 (en) 2021-06-09
PH12021550237A1 (en) 2021-10-11
CN112752570A (zh) 2021-05-04
ECSP21011795A (es) 2021-03-31
IL280471A (en) 2021-03-25
KR20210041589A (ko) 2021-04-15
WO2020028778A1 (en) 2020-02-06
TN2021000021A1 (en) 2022-10-03
TW202019414A (zh) 2020-06-01
AR115913A1 (es) 2021-03-10
MX2021001364A (es) 2021-04-13
CL2021000271A1 (es) 2021-08-20
EA202190429A1 (ru) 2021-06-15
CA3107737A1 (en) 2020-02-06
NI202100006A (es) 2021-05-21
JP2021532193A (ja) 2021-11-25
CO2021001979A2 (es) 2021-03-08
US20210205225A1 (en) 2021-07-08
BR112021001859A2 (pt) 2021-04-27
CR20210093A (es) 2021-05-28
SG11202100984VA (en) 2021-02-25
PE20211410A1 (es) 2021-08-02

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
US20210205225A1 (en) Bioavailable oral dosage forms
CN102056589B (zh) 包含bibw 2992的固体药物制剂
US10034854B2 (en) Pharmaceutical composition with improved bioavailability
CN102238945B (zh) 药物制剂514
CN108367005B (zh) 包含酪氨酸蛋白激酶抑制剂的剂型组合物
EP3616696B1 (en) Orally administrable enzalutamide-containing pharmaceutical composition
TW201102067A (en) Solid dispersions containing an apoptosis-promoting agent
CN109475553A (zh) 尼洛替尼的药物组合物
TW200418457A (en) Oral solid form pharmaceutical and pharmaceutical for the treatment of dysuria
EP3354283B1 (en) Pharmaceutical capsule composition comprising silodosin
HUP1000327A2 (en) Composition containing nanostructured ezetibime and process for it's preparation
EP3539536A1 (en) A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
EA042654B1 (ru) Биодоступные пероральные дозированные формы
WO2015199115A1 (ja) 経口投与用医薬組成物
KR20190007370A (ko) 바제독시펜 또는 그의 약제학적으로 허용가능한 염, 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는 우수한 안정성 및 용출률을 갖는 복합제제
WO2026035860A1 (en) Formulations of adenosine receptor antagonist
HK40059863A (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
WO2026035689A1 (en) Vamorolone solid oral dosage forms
AU2024317636A1 (en) Pharmaceutical composition containing substituted indol-5-ol derivative and use thereof
CN121311218A (zh) 雌激素受体降解剂的固体口服剂型
HK1258699B (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application